Latest News from Seqalis

Seqalis is proud to contribute its quantitative analytical expertise to the Oncode Accelerator Therapeutic Vaccines Workstream. Through its patented qTCR-Seq technology and collaborative approach, Seqalis helps strengthen the development of next-generation therapeutic cancer vaccines with robust, data-driven insights. Read the full article to learn how this collaboration is supporting innovation in cancer immunotherapy.

Seqalis is proud to announce its participation in a pivotal research initiative in the fight against breast cancer ! We are delighted to announce the participation of Seqalis in phase 2 of the AURORA project, led by the Breast International Group (BIG) in their pursuit of progress in breast cancer research. In this new phase, […]

Monday March 13th, Seqalis was honoured to welcome the Minister President of the Wallonia Region, M. Elio Di Rupo and the Deputy General Administrator of the Wallonia Export & Investment Agency, M. Jean-Pierre Marcelle for the visit of its facilities at Gosselies. It was a great opportunity to present the activities of Seqalis and to […]

On Jan. 25 2023, Seqalis broadcasted a live expert panel on immuno-oncology and quantitative TCR sequencing. The webinar was organized by Seqalis with the collaboration of the Institut de Duve (UCLouvain, Be) and PDC-Line Pharma (Be/Fr). The expert panel was composed of Dr Sophie Lucas, President of de Duve Institute (UCLouvain, Be), Eric Halioua, CEO […]